Becoming a Global Specialty Pharmaceutical Company
Established in 2008, Orient PHARMA (OP) is an important subsidiary of the Orient EuroPharma Group. The Company focuses on the innovative R&D and manufacturing of pharmaceuticals, and is dedicated to developing central nervous drugs. In 2017, the Company has more than 170 employees, of which 45% are R&D staff, among which more than 70% have master's and doctoral degrees.
The mission and vision of Orient Pharma is to become a Global Specialty Pharma. In the future, the Company will continue to exert its R&D power, and together with the parent company Orient EuroPharma's strong marketing teams in Taiwan and Southeast Asia, establish a foothold in Asia and expand into the international market in Europe, the Americas and China.
Unanimous Domestic and International Recognition for R&D Quality
Together with multinational and multi-center clinical trial teams, OP’s R&D has the capability to target market-oriented niche products. To date, the Company has two unique and innovative drug development technology platforms, evidencing its R&D capabilities. Located in the Huwei Science Park in Yunlin County, the Company's plant is the first pharmaceutical factory in Taiwan to be built according to PIC/S GMP, EU GMP and US FDA 21 CFR international standards. The quality and stability of all its manufactured pharmaceuticals (tablets and capsules) are ensured, and consistent with the requirements of international partners and customers.Currently, OP has achieved three US FDA drug certifications, namely for muscle relaxant Carisoprodol, diabetes drug Miglitol and lipid-lowering drug Pitavastatin. The lipid-lowering drug, developed by OP, is currently on the Taiwan market, and is also certified by Vietnam and Philippines. Methydur, a new drug for attention deficit hyperactivity disorder has also been licensed in 2018 for the Taiwan market, and will be further expanded into Southeast Asia.
2F, No. 368, Sec. 1, Fu Hsing S. Road, Taipei 106, Taiwan, R.O.C.